Highlights

Small cell lung cancer: what role does 18F-FDG PET/CT play?

Fifty-five patients were included in this study, which assesses 18F-FDG PET/CT in small cell lung cancer (SCLC) staging and metabolic (SUVmax, MTV and TLG) and morphologic (CTvol) variables as predictors for overall survival (OS) and progression-free survival (PFS).
Key Points:

• Identifying variables that predict the prognosis of patients with SCLC is important.
• 18F-FDG PET/CT influences staging of patients with SCLC.
• Metabolic parameters could be used as predictors for PFS and OS.
Authors: A. Zer, L. Domachevsky, Y. Rapson et al.